Abstract
Clostridium difficile infection (CDI) is a major public health threat worldwide. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with enhanced susceptibility to and severity of nosocomial CDI; however, the mechanisms driving this phenomenon have not been elucidated. NSAIDs alter prostaglandin (PG) metabolism by inhibiting cyclooxygenase (COX) enzymes. Here, we found that treatment with the NSAID indomethacin prior to infection altered the microbiota and dramatically increased mortality and intestinal pathology associated with CDI in mice. We demonstrate that in C. difficile-infected animals, indomethacin lead to PG deregulation, an altered proinflammatory transcriptional and protein profile, and perturbed epithelial cell junctions. These effects were paralleled by an increased recruitment of intestinal neutrophils and CD4+ cells. Together, these data implicate NSAIDs in perturbation of the gut microbiota and disruption of protective COX-mediated PG production during CDI, resulting in altered epithelial integrity and associated immune responses.
Introduction
Clostridium difficile infection (CDI) remains a leading cause of hospital-acquired diarrhea and a significant cause of morbidity and mortality, particularly among elderly populations. While the disruption of the gut microbiota by antibiotics is the most recognized risk factor, epidemiological evidence has increasingly pointed toward nonsteroidal anti-inflammatory drugs (NSAIDs) as a significant contributor to CDI severity.
NSAIDs function by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins (PGs). While PGs are mediators of pain and inflammation, they also play a critical role in maintaining the structural integrity of the intestinal lining. This study investigates the mechanisms by which NSAIDs exacerbate CDI, focusing on the interplay between the gut microbiota, the physical intestinal barrier, and the host immune response.
Methodology
To explore this synergy, researchers utilized a mouse model of antibiotic-associated CDI. Mice were first treated with the antibiotic cefoperazone to induce susceptibility to C. diff. A subset of these mice was then administered a short, two-day course of the NSAID indomethacin prior to infection.
The study employed a multi-omic approach to capture the full scope of the biological changes:
- Microbial Analysis: 16S rRNA gene sequencing was used to track shifts in the gut microbiota.
- Transcriptomics and Proteomics: Gene expression in cecal tissue was monitored via qRT-PCR and NanoString, while protein levels of inflammatory cytokines were measured using multiplex assays.
- Cellular Imaging: Transmission electron microscopy (TEM) and immunofluorescence were utilized to visualize the structural integrity of the intestinal epithelium, specifically focusing on "tight junction" proteins like Occludin and ZO-1.
- Immune Profiling: Flow cytometry identified the specific types of immune cells infiltrating the gut tissue during infection.
Key Findings
1. Disruption of the Microbial Landscape
Even in the absence of infection, indomethacin treatment significantly altered the composition of the gut microbiota. The researchers observed an enrichment of Bacteroides and Akkermansia species, alongside a decrease in Turicibacter, a genus typically associated with a healthy intestinal environment. These microbial shifts persisted for up to 11 days, suggesting that even brief NSAID exposure can have lasting effects on the gut’s ecological balance.
2. "Unzipping" the Intestinal Barrier
Perhaps the most striking finding was the physical breakdown of the intestinal wall. In mice treated with both NSAIDs and C. diff, the researchers observed a redistribution of the structural proteins Occludin and ZO-1. These proteins, which normally act as the "glue" between epithelial cells, moved from the cell junctions into the cytoplasm. This effectively "unzipped" the gut barrier, leading to increased intestinal permeability.
3. The Prostaglandin Paradox and Immune Overdrive
While NSAIDs are intended to suppress prostaglandins, the study found a paradoxical increase in PGE2 levels 72 hours post-infection in the NSAID-treated group. This suggests a late-stage dysregulation of the inflammatory response. Rather than calming the immune system, the combination of NSAIDs and CDI appeared to trigger a hyper-inflammatory state, characterized by a massive recruitment of neutrophils and Th17 cells to the gut and a significant upregulation of pro-inflammatory markers such as IL-1β, IL-6, and CXCL1.
Results and Clinical Implications
The biological consequences of these changes were severe. Pre-exposure to indomethacin increased the mortality rate of CDI from 20% to 80% in the mouse model. Furthermore, the compromised intestinal barrier allowed for bacterial translocation; NSAID-treated mice showed significantly higher loads of bacteria in their livers, indicating that a localized gut infection had transitioned into a systemic threat.
Conclusion
This research highlights a dangerous synergy between NSAIDs and C. difficile. By simultaneously altering the microbiota, weakening the physical gut barrier, and dysregulating the immune response, NSAIDs create a "perfect storm" that exacerbates the severity of CDI. While indomethacin was the primary focus of this study, the findings raise important questions regarding the use of more common over-the-counter NSAIDs like ibuprofen or aspirin in patients at risk for CDI. Future clinical research is necessary to determine if these mechanisms translate directly to human patients and to develop strategies for mitigating these risks in clinical settings.
Summary updated